DAX drifts as equities slide

As the euro continues to strengthen against the US dollar, nerves are beginning to show in the predominantly export driven Germany 30.

Linde AG and Deutsche Bank AG lead the Germany 30 lower as European equity markets selloff across the board. Bayer has warranted most of the headlines after it completed the acquisition of Merck & Co’s consumer care business. This increases the pharmaceutical company’s exposure to the ‘over the counter’ drug business, just behind Johnson & Johnson in size.

Over the course of 2014 the Germany 30 has made a succession of lower highs because it has struggled to counter both global issues like the Ukraine situation, and a eurozone yet to fully convince that its recovery is fully under way. In contrast to this EUR/USD has continued to climb and has once again broken above the $1.39 level. The European Central Bank has stated that it is watching the strength of the euro, and has stopped just short of stating what action it will take should it rise too much. The increased strength of the euro has weakened the attractiveness of German exporters and subsequently stifled the Germany 30’s ability to head higher.

Until the euro begins to weaken against the US dollar we feel the Germany 30 will be prevented from rising higher much, and the precedent of lower highs could last.

Germany 30 chart

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.